No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ABUS240621C1000
- 2.20
- 0.000.00%
15min DelayTrading Jun 13 13:51 ET
0.00High0.00Low
0.00Open2.20Pre Close0 Volume3 Open Interest1.00Strike Price0.00Turnover1291.60%IV7.93%PremiumJun 21, 2024Expiry Date1.97Intrinsic Value100Multiplier1DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type0.9578Delta0.0366Gamma1.46Leverage Ratio-0.0567Theta0.0000Rho1.40Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Express News | Morgan Stanley Reports 10.3% Passive Stake in Arbutus Biopharma Corp as of May 31- SEC Filing
Express News | HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
Chardan Capital analyst Keay Nakae maintains $Arbutus Biopharma(ABUS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 38.2% an
Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk
Arbutus Biopharma Corporation (ABUS) is currently at $3.33, down $0.30 or 8.26% --On pace for largest percent decrease since April 25, 2023, when it fell 12.46% --Currently down two of the past thre
Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants w
Express News | Treatment With Arbutus’ Imdusiran and Vtp-300 Achieves Statistical Significance in Lowering Hbsag Levels
Comments
$Arbutus Biopharma(ABUS.US$ $Barinthus Biotherapeutics(BRNS.US$ Arbutus Biopharma (ABUS) said Thursday data from a phase 2a trial in patients with chronic hepatitis B virus infection showed that treatment with imdusiran followed by Barinthus Biotherapeutics' (BRNS) VTP-300 was generally safe and well-tolerated.
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
...
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
...
$Arbutus Biopharma(ABUS.US$
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks ...
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks ...
2
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
11
2
Arbutus Biopharma's worrying high P/S ratio is underscored by its falling revenue. Investors could pay a steep premium as these declines might significantly affect the stock's value.
Read more